TransCode Names Dr. Anna Moore SAB Chair, Signs MSU Research Deal
TransCode Therapeutics has appointed co-founder Anna Moore, PhD, as Chair of its Scientific Advisory Board to guide its RNA-based cancer therapy research. The company signed a sponsored research agreement with Michigan State University to accelerate development and combination studies of its lead candidate TTX-MC138 with Seviprotimut-L and standard therapies.
1. Appointment of Scientific Advisory Board Chair
TransCode has appointed Dr. Anna Moore, co-founder and Associate Dean for Research Development at Michigan State University, as Chair of its Scientific Advisory Board. Dr. Moore brings 26 years of experience at Massachusetts General Hospital and Harvard Medical School, where she led the Molecular Imaging Laboratory and advanced RNA-targeted oncology research.
2. Sponsored Research Agreement with Michigan State University
Under the new agreement, Michigan State University researchers will work to advance TransCode’s lead candidate, TTX-MC138, through preclinical evaluation in combination with Seviprotimut-L and standard-of-care therapies. The collaboration aims to fast-track pipeline candidates from laboratory studies into clinical development and identify potential synergistic effects.